The IL-6 / JAK / Stat 3 Feed-Forward Loop Drives Tumorigenesis and Metastasis 1 , 2

We have investigated the importance of interleukin-6 (IL-6) in promoting tumor growth and metastasis. In human primary breast cancers, increased levels of IL-6 were found at the tumor leading edge and positively correlated with advanced stage, suggesting a mechanistic link between tumor cell production of IL-6 and invasion. In support of this hypothesis, we showed that the IL-6/Janus kinase (JAK)/signal transducer and activator of transcription 3 (Stat3) pathway drives tumor progression through the stroma and metastatic niche. Overexpression of IL-6 in tumor cell lines promoted myeloid cell recruitment, angiogenesis, and induced metastases. We demonstrated the therapeutic Abbreviations: IL-6, interleukin-6; JAK, Janus kinase; LVI, lymphovascular invasion; MFP, mammary fat pad; MDSCs, myeloid-derived suppressor cells; Stat3, signal transducer and activator of transcription 3; TN, triple negative Address all correspondence to: Jacqueline Bromberg, MD, PhD, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 397, New York, NY 10021. E-mail: bromberj@mskcc.org or David Lyden, MD, PhD, Departments of Pediatrics and Cell Biology, Weill Cornell Medical College, 515 E. 71st Street, S726, Box 284, New York, NY 10021. E-mail: dcl2001@med.cornell.edu Our work was supported by grants from the National Institutes of Health [U54: CA148967 (J.B. and G.A.-B.) and R01: CA87637 (J.B.)], Charles and Marjorie Holloway Foundation (J.B.), Sussman Family Fund (J.B.), Lerner Foundation (J.B.), AstraZeneca (J.B.), Breast Cancer Alliance (J.B.), Manhasset Women’s Coalition Against Breast Cancer (J.B.), NYS Women’s Bowling Association (J.B.), American Hellenic Educational Progressive Association 5th District (E.B. and D.L.), Department of Defense (Postdoctoral Award W81XWH-10-1-1013) and Fondazione Carisbo di Bologna (P.S.), Children’s Cancer and Blood Foundation (D.L.), The Manning Foundation (D.L.), The Hartwell Foundation (D.L.), Pediatric Oncology Experimental Therapeutics Investigators Consortium (D.L.), Stavros S. Niarchos Foundation (D.L.), Champalimaud Foundation (D.L.), The Nancy C. and Daniel P. Paduano Foundation (D.L.), The Mary Kay Foundation (D.L.), The Malcolm Hewitt Wiener Foundation (D.L.), The George Best Costacos Foundation (D.L.), National Cancer Institute [R01CA 098234-01 and U54-CA143836 PSOC training grant (D.L.)], Susan G. Komen for the Cure (D.L.), and The Beth C. Tortolani Foundation (J.B. and D.L.). J.B. has consulted for Roche, Medimmune, and Bristol-Myers Squibb and has received research support from AstraZeneca. No potential conflicts of interest were disclosed by the other authors. This article refers to supplementary materials, which are designated by Table W1 and Figures W1 to W4 and are available online at www.neoplasia.com. These authors contributed equally to the manuscript. Received 26 March 2013; Revised 19 April 2013; Accepted 22 April 2013 Copyright © 2013 Neoplasia Press, Inc. All rights reserved 1522-8002/13/$25.00 DOI 10.1593/neo.13706 *Department of Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY; Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, Cell and Developmental Biology,Weill Cornell Medical College (WCMC), New York, NY; Hofstra North Shore-LIJ School of Medicine, Manhasset, NY; Computational Biology Program, MSKCC, NewYork, NY; Department ofMolecular Pharmacology, MSKCC, New York, NY; Antitumor Assessment,MSKCC, NewYork, NY; **Molecular Cytology, MSKCC, New York, NY; Immunology Program, Sloan-Kettering Institute, MSKCC, New York, NY; Department of Experimental, Diagnostic and Specialty Medicine, Policlinico Universitario S. Orsola-Malpighi, Bologna, Italy; Department of Medical and Surgical Sciences, Policlinico Universitario S. Orsola-Malpighi, Bologna, Italy; Department of Anatomy and Histological Pathology, Policlinico Universitario S. Orsola-Malpighi, Bologna, Italy; Tumor Microenvironment Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD; ***Champalimaud Metastasis Programme, Lisbon, Portugal; TokyoMedical University, Tokyo, Japan; Oncology iMED, AstraZeneca, Waltham, MA; Department of Pediatrics, MSKCC, New York, NY; WCMC, New York, NY www.neoplasia.com Volume 15 Number 7 July 2013 pp. 848–862 848

[1]  T. Putoczki,et al.  Stat3: Linking inflammation to (gastrointestinal) tumourigenesis , 2012, Clinical and experimental pharmacology & physiology.

[2]  G. Prendergast,et al.  IDO is a nodal pathogenic driver of lung cancer and metastasis development. , 2012, Cancer discovery.

[3]  R. Figlin,et al.  S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. , 2012, Cancer cell.

[4]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[5]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[6]  E. Galun,et al.  Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis , 2012, Clinical and Translational Oncology.

[7]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[8]  W. Gerald,et al.  Stat3 Mediates Expression of Autotaxin in Breast Cancer , 2011, PloS one.

[9]  R. Figlin,et al.  Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. , 2011, Cancer research.

[10]  D. Levy,et al.  STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. , 2011, Cancer research.

[11]  S. Dave,et al.  HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. , 2011, Cancer research.

[12]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[13]  M. Wicha,et al.  Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory Roots , 2011, Clinical Cancer Research.

[14]  Hua Yu,et al.  Stat3-induced S1PR1 expression is critical for persistent Stat3 activation in tumors , 2010, Nature Medicine.

[15]  Sun Park,et al.  STAT3 transcriptional factor activated by reactive oxygen species induces IL6 in starvation-induced autophagy of cancer cells , 2010, Autophagy.

[16]  R. Figlin,et al.  Microenvironment and Immunology Targeting Stat3 in the Myeloid Compartment Drastically Improves the in Vivo Antitumor Functions of Adoptively Transferred T Cells , 2022 .

[17]  P. Musiani,et al.  Stat3 is required for anchorage‐independent growth and metastasis but not for mammary tumor development downstream of the ErbB‐2 oncogene , 2009, Molecular carcinogenesis.

[18]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[19]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[20]  Hua Yu,et al.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.

[21]  D. Levy,et al.  Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. , 2009, Cancer research.

[22]  F. Vesuna,et al.  Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells , 2009, Oncogene.

[23]  A. Richardson,et al.  Reciprocal Effects of STAT5 and STAT3 in Breast Cancer , 2009, Molecular Cancer Research.

[24]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[25]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[26]  Hua Yu,et al.  Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. , 2008, The Journal of clinical investigation.

[27]  K. Hunter,et al.  Mouse Modifier Genes in Mammary Tumorigenesis and Metastasis , 2008, Journal of Mammary Gland Biology and Neoplasia.

[28]  Z. Werb,et al.  GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. , 2008, Cancer cell.

[29]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[30]  D. Santini,et al.  IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. , 2007, The Journal of clinical investigation.

[31]  W. Gerald,et al.  Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer , 2007, Breast Cancer Research.

[32]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[33]  M. Colombo,et al.  The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.

[34]  R. Kaplan,et al.  Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond , 2007, Cancer and Metastasis Reviews.

[35]  S. Rafii,et al.  Preparing the "soil": the premetastatic niche. , 2006, Cancer research.

[36]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[37]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[38]  Goberdhan P Dimri,et al.  Mammary epithelial cell transformation: insights from cell culture and mouse models , 2005, Breast Cancer Research.

[39]  R. Arlinghaus,et al.  Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. , 2005, Cancer research.

[40]  P. Sinha,et al.  Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1 , 2005, The Journal of Immunology.

[41]  J. Gregg,et al.  Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior , 2005, Clinical & Experimental Metastasis.

[42]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[43]  T. Kishimoto,et al.  Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody , 2004, Springer Seminars in Immunopathology.

[44]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[45]  D. Gabrilovich,et al.  Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species , 2003, Journal of leukocyte biology.

[46]  David L Rimm,et al.  Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[48]  S. Barsky,et al.  A novel human xenograft model of inflammatory breast cancer. , 1999, Cancer research.

[49]  S G Hilsenbeck,et al.  Significance of axillary lymph node metastasis in primary breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  F. Miller,et al.  Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. , 1992, Cancer research.